IP Verse

Nalmefene For Reduction Of Alcohol Consumption In Specific Target Populations

EP3138564

H. LUNDBECK A/S
Application Number
EP16187426A
Filing Date
Jun 27, 2013
Status
Revoked
Feb 20, 2024
Grant Date
Jan 31, 2018
External Links
Slate, Register

Biblio Summary

The patent EP3138564B1 was granted on Jan 31, 2018 by H. Lundbeck A/S The patent is currently Revoked.

Oppositions Filed by other Companies on the Patent

The table below shows 1 patent oppositions filed on the patent at EPO, listing each opposing company and filing date. Tracking these filings indicates that the applicant is active in this industry, while opposing companies may be signaling their own interest in competing within the same space. These disputes are essential for insights into competitor actions, patent strategy and emerging technological trends.

CompanyOpposition DateOpposition Status

Get instant alerts for new oppositions and patent status changes

ALFRED E. TIEFENBACHER (GMBH & CO. KG)Oct 30, 2018 N.A.

More Opposed Patents of H. Lundbeck A/S

The table below shows the patents of H. Lundbeck A/S that have been opposed by other companies.

Patent NumberTitleGrant DateOpposition Count
EP2608789Therapeutic Uses Of 1-[2-(2,4-Dimethyl-Phenylsulfanyl)Phenyl]PiperazineAug 21, 20241
EP3345604Nalmefene For Reduction Of Alcohol Consumption In Specific Target PopulationsJun 7, 20232
EP3615518Process For The Manufacture Of Vortioxetine Hbr Alpha-FormDec 15, 20211

Dossier Documents of the Patent

The documents dossier of the patent at EPO including all essential records in the patent's lifecycle, from filing to grant to oppositions.

  • Date

    Description

  • Get instant alerts for new documents